The latest group of winning technologies has a little something for everyone—from scientists at the lab bench to those in the clinic and even the classroom.
For the past decade, scientists have relied almost exclusively on CRISPR-Cas systems for genome editing. Now, a smaller but equally efficient nuclease is here to compete.
Even as CRISPR-based tools become a lab staple, scientists strive to tackle the associated technological challenges to improve their efficacy and safety.
In this webinar, Douglas Marchuk and Viviana Gradinaru will discuss how scientists can overcome physiological barriers preventing gene therapies from reaching the brain.
A new iPSC-derived cellular tool with built-in Cas9 expression enables high efficiency knockout screening for drug target identification and validation.